This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Treosulfan
- DrugBank Accession Number
- DB11678
- Background
Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Treosulfan (DB11678)
- Weight
- Average: 278.29
Monoisotopic: 278.013009759 - Chemical Formula
- C6H14O8S2
- Synonyms
- DIHYDROXYBUSULFAN
- OVASTAT
- Treosulfan
- External IDs
- NSC-39069
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareDarbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Treosulfan. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Treosulfan. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Treosulfan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Treosulfan. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Trecondi Injection, powder, for solution 5 g Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2020-12-16 Not applicable EU 
Trecondi Injection, powder, for solution 1 g Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2020-12-16 Not applicable EU Trecondi Injection, powder, for solution 5 g Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2020-12-16 Not applicable EU Trecondi Injection, powder, for solution 1 g Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mb H 2020-12-16 Not applicable EU Trecondyv Powder 5 g / vial Intravenous Medexus Inc 2021-08-31 Not applicable Canada 
Trecondyv Powder 1 g / vial Intravenous Medexus Inc Not applicable Not applicable Canada
Categories
- ATC Codes
- L01AB02 — Treosulfan
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organosulfonic acid esters. These are esters of sulfonic acid, which have the general structure RS(=O)2OR' (R,R' = organyl, not H).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic sulfonic acids and derivatives
- Sub Class
- Organosulfonic acids and derivatives
- Direct Parent
- Organosulfonic acid esters
- Alternative Parents
- Sulfonic acid esters / Sulfonyls / Methanesulfonates / Secondary alcohols / 1,2-diols / Organic oxides / Hydrocarbon derivatives
- Substituents
- 1,2-diol / Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Methanesulfonate / Organic oxide / Organic oxygen compound / Organooxygen compound / Organosulfonic acid ester / Organosulfur compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- methanesulfonate ester (CHEBI:82557)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- CO61ER3EPI
- CAS number
- 299-75-2
- InChI Key
- YCPOZVAOBBQLRI-WDSKDSINSA-N
- InChI
- InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1
- IUPAC Name
- (2S,3S)-2,3-dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonate
- SMILES
- CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
References
- General References
- EMA Summary of Product Characteristics: Trecondi (treosulfan) powder for solution for infusion [Link]
- External Links
- KEGG Compound
- C19557
- PubChem Compound
- 9882105
- PubChem Substance
- 347828046
- ChemSpider
- 8057780
- 38508
- ChEBI
- 82557
- ChEMBL
- CHEMBL455186
- ZINC
- ZINC000001671094
- Wikipedia
- Treosulfan
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous 1 G Injection, powder, for solution Intravenous 5 G Powder Intravenous 1 g / vial Powder Intravenous 5 g / vial Powder, for solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 17.0 mg/mL ALOGPS logP -1.5 ALOGPS logP -2.6 ChemAxon logS -1.2 ALOGPS pKa (Strongest Acidic) 12.99 ChemAxon pKa (Strongest Basic) -3.5 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 127.2 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 51.98 m3·mol-1 ChemAxon Polarizability 24.93 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 20:39 / Updated at June 27, 2022 14:55